September 19, 2019

Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities...
Read more
September 18, 2019

BONESUPPORT HOLDING AB presents health economic evidence

Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids announced...
Read more
September 17, 2019

Nordic Nanovector R&D Day unveils updates on several programs

17.09.2019 07:00 Clinical          LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complet...
Read more
September 16, 2019

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”)  announced that Nasdaq Stockholm’s listing commit...
Read more
September 15, 2019

New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop

Stockholm – September 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 stud...
Read more
September 12, 2019

Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

Stockholm – September 11, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that clinical trial data were presented at the Society of Hematologic Oncology (SO...
Read more
September 11, 2019

Vicore Pharma has been approved for listing on Nasdaq Stockholm

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (”Vicore”) application to be listed on Nasdaq Sto...
Read more
September 9, 2019

Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harr...
Read more
September 6, 2019

Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

Gothenburg, September 6, 2019 - Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announced today that...
Read more
September 4, 2019

Nordic Nanovector to participate in three upcoming investor conferences in the US

Oslo, Norway, 4 September 2019 Nordic Nanovector ASA (OSE: NANO) announces that its CEO, Eduardo Bravo, will participate and present at the following upcoming investor...
Read more